Nuveen
ARCT icon

Nuveen’s Arcturus Therapeutics ARCT Stock Holding History

Nuveen’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-51,200
Closed -$1K – 3249
2022
Q1 		$1K Buy
+51,200
New +$1.31M ﹤0.01% 3376
2021
Q4 		– Sell
-51,200
Closed -$3K – 3323
2021
Q3 		$3K Buy
+51,200
New +$2.29M ﹤0.01% 3400
2021
Q2 		– Sell
-102,200
Closed -$4K – 3360
2021
Q1 		$4K Hold
102,200
– – ﹤0.01% 3338
2020
Q4 		$4K Buy
+102,200
New +$6.92M ﹤0.01% 3278

Other funds holding ARCT

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Empire Life Investments
Empire Life Investments Toronto, Ontario, Canada $1.83B AUM 33.18% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Nuveen's ARCT Position: Q3 2026 in Review

Nuveen increased its Arcturus Therapeutics (ARCT) stake by 15% in Q3 2026, buying an estimated $83K and bringing the position to 60,481 shares worth $828K. The position accounts for ﹤0.01% of the portfolio, ranked #3111.

Nuveen first reported a position in ARCT in Q2 2020 and has held it in 26 quarters since. The position peaked at $6.14M in Q4 2023. 70 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.

  • Nuveen held 60,481 shares of Arcturus Therapeutics worth $828K as of Q3 2026.
  • Nuveen bought 7,939 Arcturus Therapeutics shares in Q3 2026, an estimated $83K.
  • Arcturus Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #3111 holding.
  • Nuveen first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 26 quarters since.
  • Nuveen's Arcturus Therapeutics position peaked at $6.14M in Q4 2023.
  • 70 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.